Screener / SEC EDGAR /CIK 0001638833 /10-K filed Mar 2, 2026, compared with Mar 7, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Hospitals

Surgery Partners, Inc. SGRY

Compare with peers Embed
New in the 10-K 4 paragraphs with nothing like them in the 10-K filed Mar 7, 2025 New in the 10-Q 55 paragraphs not in the 10-Q filed Aug 10, 2026 10-Q against the 10-K 28 risk factor paragraphs and sentences added or reworded

New risk paragraphs, branching off last year

Each branch is a paragraph in Risk Factors with nothing like it in the 10-K filed Mar 7, 2025. A box jumps to the paragraph as filed, below.

4 new

Paragraphs with nothing like them in last year's 10-K

Quoted exactly

4 paragraphs in Risk Factors of the 10-K filed Mar 2, 2026 with nothing like them in the 10-K filed Mar 7, 2025. Quoted exactly. Paragraphs that were only edited are under 10-K change.

As of December 31, 2025, we and our subsidiaries had approximately $3.7 billion aggregate principal amount of indebtedness outstanding, which includes approximately $1.4 billion principal amount of senior secured term loans (the "Term Loan") outstanding and $1,225.0 million senior unsecured notes due 2032 (the "2032 Unsecured Notes"). As of December 31, 2025, we had no outstanding

Read in the 10-K

compliance with the diverse privacy requirements in all of the jurisdictions in which we do business. If we fail to comply with HIPAA or similar state laws, we could incur substantial civil monetary or criminal penalties.

Read in the 10-K

Over the past several years, various laws and regulations lengthened the enrollment period, expanded income eligibility, and reduced premium caps for subsidies for individuals purchasing Affordable Care Act coverage through state and federal marketplaces. However, several of these provisions – notably, those relating to premium caps for subsidies – expired on December 31, 2025. The failure of Congress to renew these subsidies through legislative action is widely anticipated to result in significant increases in premiums, potentially leading to decreased enrollment and a corresponding rise in the number of uninsured individuals or a shift of individuals from commercial coverage to government program coverage in 2026. As a direct effect of these changes, the Company may experience decreased patient volumes, reduced revenues and an increase in uncompensated care, which would adversely affect the Company’s results of operations and cash flows. We cannot predict whether or how the Congress may further extend (or decline to extend) or modify provisions of or relating to the Affordable Care Act or other laws affecting the healthcare industry generally, nor can we predict how the current administration will influence, promulgate or implement rules, regulations or executive orders that affect the healthcare industry directly or indirectly (including, for example, through changes resulting from the provisions of the OBBBA). We may also experience potential impacts on our business, in ways we cannot anticipate, from healthcare-related policy changes at the state level. Some federal and state changes, initiatives and requirements could, among other things, negatively impact our patient volumes, case mix and revenue mix, increase our operating costs, adversely affect the reimbursement we receive for our services, impact our competitive position or require us to expend resources to modify certain aspects of our operations, any of which could have an adverse effect on our financial condition, results of operations or cash flows. Furthermore, we cannot predict the impact healthcare policy risks and uncertainties may have on the trading price of our common stock.

Read in the 10-K

be inconsistent with applicable laws, we may be required to restructure or discontinue such programs, or be subject to other significant penalties.

Read in the 10-K

Paragraphs in the 10-Q filed Nov 9, 2026 that were not in the one before

New in the latest 10-Q

55 paragraphs in the 10-Q filed Nov 9, 2026 with nothing like them in the 10-Q filed Aug 10, 2026 (at least half the words must differ; new numbers alone do not count). Quoted exactly, grouped by the item heading above them. This is text that changed, not a judgement of how serious it is.

Financial statements and notes

On July 6, 2026, the Company revised its internal organizational structure, resulting in a change to its reporting units for purposes of goodwill impairment testing. The Company's former National and American reporting units were reorganized into the North, South, and West reporting units. In connection with this change, goodwill was reassigned to the revised reporting units during July 2026 using a relative fair value allocation approach. The Company performed goodwill impairment assessments immediately before and after the reassignment and concluded that no impairment existed. The reassignment did not affect the total carrying amount of goodwill.

Read in the 10-Q

Carrying Amount Fair Value September 30, December 31, September 30, December 31,

Read in the 10-Q

• On September 14, 2026, the Company completed the previously announced sale of its ownership interests in Mountain View Hospital, LLC (“MVH”), Idaho Falls Community Hospital, LLC (“IFCH”) and associated subsidiaries to Intermountain Health (the “Idaho Transaction”). The disposed business consisted of the hospital operations of MVH and IFCH, including substantially all assets and certain liabilities associated with such operations. The Company received aggregate consideration of approximately $ 796.6 million, consisting of consideration for the ownership interests sold to Intermountain Health and termination of the Company's management agreement with MVH. The carrying amounts of assets and liabilities of the disposed business as of the closing date were approximately $ 1,195.5 million and $ 463.4 million, respectively.

Read in the 10-Q

The following table sets forth operating results associated with the disposed business through the closing date of the transaction (in millions):

Read in the 10-Q

During 2026, the Company made a voluntary prepayment of $ 285.0 million on its senior secured term loan (the "Term Loan") without premium or penalty. As a result of the prepayment, the Term Loan is no longer subject to quarterly payments prior to maturity. In connection with prepayment, the Company wrote-off a portion of unamortized debt issuance costs and discounts, resulting in a loss on debt extinguishment of $ 3.7 million, included in loss on debt extinguishment in the accompanying condensed consolidated statements of operations.

Read in the 10-Q
Show the other 50

As of September 30, 2026, the Company had five interest rate caps with a total notional amount of $ 1,365.0 million, of which, $ 1,080.9 million is designated in a cash flow hedging relationship and $ 284.1 million is undesignated. The interest rate caps each have a termination date of December 31, 2028. In connection with the voluntary prepayment on the Term Loan in 2026 (see Note 3. "Long-Term Debt"), the Company de-designated a portion of one of its interest rate caps. The amount of unrealized losses recorded in other comprehensive income ("OCI") related to the de-designated notional amount at the time of the de-designation was $ 0.3 million. This amount was reclassified from accumulated OCI into income and is included as a component of other income in the condensed consolidated statements of operations for the three and nine months ended September 30, 2026. No cash was exchanged between the Company and the counterparties due to the de-designation, therefore the non-cash transactions had no impact on the condensed consolidated statements of cash flows.

Read in the 10-Q

(1) Loss reclassified from accumulated OCI upon de-designation of a portion of one of the Company's interest rate caps.

Read in the 10-Q

On October 23, 2026, the Company entered into an Agreement and Plan of Merger (the “Original Merger Agreement”) with Spyglass Topco, LLC (“Parent”), a Delaware limited liability company, Spyglass Merger Subsidiary, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (“Merger Subsidiary”), and, solely for the limited purposes set forth therein, Bon Secours Mercy Health, Inc., a Maryland nonstock, nonprofit corporation, which was further amended on November 8, 2026 by that certain Amendment No. 1 to Agreement and Plan of Merger (the “Merger Agreement Amendment,” and together with the Original Merger Agreement, the “Amended Merger Agreement”). Pursuant to the Amended Merger Agreement, and on the terms and subject to the conditions therein, Merger Subsidiary will merge with and into the Company (the “Merger”), with the Company surviving the Merger as a wholly-owned subsidiary of Parent (the “Surviving Company”). If the Merger is consummated, the Company’s common stock will be delisted from the Nasdaq Global Select Market and deregistered under the Securities Exchange Act of 1934, as amended.

Read in the 10-Q

On the terms and subject to the conditions of the Amended Merger Agreement, at the effective time of the Merger (the “Effective Time”), each issued and outstanding share of Company common stock as of immediately prior to the Effective Time (other than certain excluded shares, including the Rollover Shares (as defined below)) will be converted into the right to receive $ 25.00 in cash, without interest (the “Per Share Consideration”). The Merger Agreement Amendment further provides in the event the requisite Company stockholder approval has been obtained but the Merger has not occurred by March 1, 2027, the Company’s stockholders (other than certain excluded shares, including shares held by rollover stockholders) will receive additional monthly cash payments (the "Ticking Fee"), which payments will be paid in equal monthly installments in arrears at a rate equal to 10 % per annum on the $ 25.00 per share merger consideration. Based on the outside date of October 23, 2027, the maximum Ticking Fee that may be paid per share of the Company common stock is $ 1.61.

Read in the 10-Q

Concurrently with the execution and delivery of the Original Merger Agreement, the Company and Parent entered into a Voting and Support Agreement (the “Support Agreement”) with certain stockholders party thereto. Under the Support Agreement, the subject stockholders have agreed, among other things, to vote their shares of Company common stock in favor of the adoption of the Amended Merger Agreement. In addition, under the Support Agreement, immediately prior to the closing of the Merger, the rollover stockholders will contribute to Parent, directly or indirectly, all of their shares of Company common stock (the “Rollover Shares”) in exchange for equity interests in Parent. The Rollover Shares will not be entitled to receive the Per Share Consideration or Ticking Fees and will, by virtue of the Merger, be converted into shares of common stock of the Surviving Corporation such that the Rollover Shares represent the same percentage of the Surviving Corporation immediately following the Effective Time as the rollover stockholders owned of the Company immediately prior to the Effective Time.

Read in the 10-Q

Completion of the Merger is subject to the satisfaction or waiver of certain customary closing conditions, including the adoption of the Amended Merger Agreement by the Company’s stockholders and receipt of required regulatory approvals under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The Amended Merger Agreement also contains customary termination provisions and provides for an approximately $ 149.1 million termination fee payable by the Company to Parent under certain circumstances. In certain circumstances, the Company may be required to reimburse Parent for certain reasonable and documented out-of-pocket expenses incurred in connection with the Merger, up to an aggregate cap of $ 8.25 million.

Read in the 10-Q

The Company has incurred and expects to incur additional transaction-related costs, including financial advisory, legal, accounting and other professional fees, in connection with the proposed Merger. The amount of future transaction-related costs cannot currently be reasonably estimated.

Read in the 10-Q

On October 23, 2026, the Company entered into an Agreement and Plan of Merger with Spyglass Topco, LLC, Merger Subsidiary, and, solely for the limited purposes set forth therein, Bon Secours Mercy Health, Inc., which was further amended on November 8, 2026 by the Merger Agreement Amendment. Pursuant to the Amended Merger Agreement and subject to the conditions therein, Merger Subsidiary will merge with and into the Company, with the Company surviving the Merger as a wholly-owned subsidiary of Parent and subject to the conditions therein, Merger Subsidiary will merge with and into the Company, with the Company surviving the merger as a wholly-owned subsidiary of Parent. If the Merger is consummated, the Company’s common stock will be delisted from the Nasdaq Global Select Market and deregistered under the Securities Exchange Act of 1934, as amended.

Read in the 10-Q

On the terms and subject to the conditions of the Amended Merger Agreement, at the Effective Time of the Merger, each issued and outstanding share of Company common stock as of immediately prior to the Effective Time (other than certain excluded shares, including the Rollover Shares) will be converted into the Per Share Consideration of $25.00 in cash, without interest. The Merger Agreement Amendment further provides in the event the requisite Company stockholder approval has been obtained but the Merger has not occurred by March 1, 2027, the Company’s stockholders (other than certain excluded shares, including shares held by rollover stockholders) will receive additional monthly Ticking Fee cash payments, which payments will be paid in equal monthly installments in arrears at a rate equal to 10% per annum on the $25.00 per share merger consideration. Based on the outside date of October 23, 2027, the maximum Ticking Fee that may be paid per share of the Company common stock is $1.61.

Read in the 10-Q

Concurrently with the execution and delivery of the Original Merger Agreement, the Company and Parent entered into a Voting and Support Agreement (the “Support Agreement”) with certain stockholders party thereto. Under the Support Agreement, the subject stockholders have agreed, among other things, to vote their shares of Company common stock in favor of the adoption of the Amended Merger Agreement. In addition, under the Support Agreement, immediately prior to the closing of the Merger, the rollover stockholders will contribute to Parent, directly or indirectly, all of their Rollover Shares in exchange for equity interests in Parent. The Rollover Shares will not be entitled to receive the Per Share Consideration or Ticking Fees and will, by virtue of the Merger, be converted into shares of common stock of the Surviving Corporation such that the Rollover Shares represent the same percentage of the Surviving Corporation immediately following the Effective Time as the rollover stockholders owned of the Company immediately prior to the Effective Time.

Read in the 10-Q

Completion of the Merger is subject to the satisfaction or waiver of certain customary closing conditions, including the adoption by the Company’s stockholders and receipt of required regulatory approvals under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The Amended Merger Agreement also contains customary termination provisions and provides for an approximately $149.1 million termination fee payable by the Company to Parent under certain circumstances. In certain circumstances, the Company may be required to reimburse Parent for certain reasonable and documented out-of-pocket expenses incurred in connection with the Merger, up to an aggregate cap of $8.25 million.

Read in the 10-Q

The Company has incurred and expects to incur additional transaction-related costs, including financial advisory, legal, accounting and other professional fees, in connection with the proposed Merger. The amount of future transaction-related costs cannot currently be reasonably estimated.

Read in the 10-Q

Loss on Debt Extinguishment. We incurred a loss on debt extinguishment of $3.7 million for the three months ended September 30, 2026 related to a voluntary prepayment of $285.0 million on our Term Loan (See Note 3. "Long-Term Debt" to our condensed consolidated financial statements).

Read in the 10-Q

Loss on Debt Extinguishment. We incurred a loss on debt extinguishment of $3.7 million for the nine months ended September 30, 2026 related to a voluntary prepayment of $285.0 million on our Term Loan (See Note 3. "Long-Term Debt" to our condensed consolidated financial statements).

Read in the 10-Q

Risk Factors

We may not complete the Merger within the anticipated timeframe, or at all, which could have a material adverse impact on our business, financial condition or results of operations, as well as negatively impact the per share price of our common stock.

Read in the 10-Q

On October 23, 2026, we entered into the Original Merger Agreement which was further amended on November 8, 2026 by the Merger Agreement Amendment. For more information, see Note 11, Subsequent Events, in Item 1 of this report. The consummation of the Merger is subject to the satisfaction or waiver, to the extent permitted by law, of certain customary closing conditions, as set forth in the Amended Merger Agreement, including, but not limited to: (i) the adoption of the Amended Merger Agreement by the Company’s stockholders; (ii) the expiration or termination of any applicable waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended; and (iii) the absence of any law or order enjoining or otherwise prohibiting the Merger. In addition, the obligation of each party to consummate the Merger is conditioned upon the other party’s representations and warranties being true in all respects (subject to certain customary materiality exceptions) and the other party having performed in all material respects its covenants, obligations and conditions under the Amended Merger Agreement. The obligation of Parent and Merger Subsidiary to consummate the Merger is also subject to the absence of a Material Adverse Effect (as defined in the Amended Merger Agreement) on the Company that is continuing. A number of the conditions to completion of the Merger are not within our control, and, in addition, the Merger may fail to close for other reasons. We cannot provide any assurance that the Merger will be consummated on the terms specified in the Amended Merger Agreement, within the anticipated timeframe or at all.

Read in the 10-Q

Failure to complete the Merger within the anticipated timeframe, or at all, could adversely affect our business and the market price of our common stock in a number of ways, including:

Read in the 10-Q

• The price of our common stock may decline to the extent that current market price of our common stock reflects assumptions that the Merger will be completed and/or completed on a timely basis;

Read in the 10-Q

• The failure to complete the Merger may result in negative publicity and negatively affect our relationship with our stockholders, employees or our other business relationships;

Read in the 10-Q

• If the Merger is not completed, the time and resources committed by our management team could have been devoted to pursuing other business opportunities and initiatives; and

Read in the 10-Q

• Under specified circumstances, upon termination of the Amended Merger Agreement, we may be required to pay Parent a termination fee of approximately $149.1 million and reimburse Parent for certain reasonable and documented out-of-pocket expenses incurred in connection with the Merger, up to an aggregate cap of $8.25 million. These payments could have a material adverse impact on our business, financial condition, or results of operations.

Read in the 10-Q

The announcement and pendency of the Merger could materially adversely affect our business, financial condition or results of operations, as well as negatively impact the share price of our common stock.

Read in the 10-Q

The pending Merger, and the announcement thereof, as well as any delays in the expected timeframe, could cause disruption in and create uncertainties, which could have an adverse effect on our business, operating results, financial condition and trading price of our common stock, regardless of whether the Merger is completed, and could cause us not to realize some or all of the benefits that we expect to achieve if the Merger is successfully completed within its expected timeframe. These risks include, but are not limited to:

Read in the 10-Q

• A substantial amount of our management’s and employees’ attention has been and will continue to be directed toward the consummation of the Merger and thus is being diverted from our day-to-day operations;

Read in the 10-Q

• There may be potential adverse reactions or changes to business relationships with our customers, health system and joint venture partners, suppliers, vendors, employees and other business partners resulting from the announcement or completion of the Merger, including if existing or potential business partners or employees attempt to negotiate changes in existing business

Read in the 10-Q

relationships, consider entering into business relationships with parties other than us, delay or defer decisions concerning their business with us, or terminate their existing business relationships with us while the Merger is pending; and

Read in the 10-Q

• There may be developments beyond our control, including, but not limited to, developments in macro-economic and industry conditions that may affect the timing or success of the Merger.

Read in the 10-Q

We have incurred, and will continue to incur, direct and indirect costs as a result of the proposed Merger.

Read in the 10-Q

We have incurred, and will continue to incur, significant costs and expenses, including legal, financial, accounting and other advisory fees and other transaction costs, in connection with the proposed Merger. These costs may exceed our expectations as a result of unexpected factors or events, and any delay in consummation could result in additional transaction-related costs and expenses. We will be required to pay a substantial portion of these costs and expenses whether or not the proposed Merger is completed and may receive little or no benefit from them if it is not completed. There are a number of factors beyond our control that could affect the total amount or the timing of these costs and expenses. Additionally, the Amended Merger Agreement also contains customary termination provisions and provides for an approximately $149.1 million termination fee payable by the Company to Parent under certain circumstances. In certain circumstances, the Company may be required to reimburse Parent for certain reasonable and documented out-of-pocket expenses incurred in connection with the Merger, up to an aggregate cap of $8.25 million.

Read in the 10-Q

Restrictions in the Amended Merger Agreement could limit our ability to pursue business opportunities while the Merger is pending.

Read in the 10-Q

Due to certain restrictions in the Amended Merger Agreement on the conduct of our business prior to completing the Merger, we may be unable (without Parent’s prior written consent, not to be unreasonably withheld, conditioned or delayed, subject to the exceptions set forth in the Amended Merger Agreement), during the pendency of the Merger, to pursue certain strategic transactions, undertake certain significant financing transactions and otherwise pursue other actions, even if such actions would prove beneficial.

Read in the 10-Q

Uncertainties associated with the Merger may cause a loss of our employees during the pendency of the Merger and under Parent’s ownership following the Merger.

Read in the 10-Q

Our current and prospective employees may experience uncertainty about their future roles under Parent’s management following the Merger, which may materially adversely affect our ability to attract, retain, and motivate key personnel during the pendency of the Merger. Our employees could lose productivity as a result of uncertainty regarding their employment following the Merger. Key personnel may depart the Company because of issues relating to the uncertainty and difficulty of the post-closing operations of our business or a desire not to remain with the Company under Parent’s management following the Merger. Accordingly, no assurance can be given that we will be able to retain key employees to the same extent that we have been able to in the past. We may lose significant expertise and talent relating to our business. The loss of any member of the senior management team could impair our ability to execute our business plan and growth strategy, have a negative impact on our revenues and the effective working relationships that our executive management have developed and cause employee morale problems and the loss of additional key employees and business partners.

Read in the 10-Q

We may be the target of securities class action and derivative lawsuits that could result in substantial costs and may delay or prevent the Merger from being completed.

Read in the 10-Q

We may in the future be the target of securities class action and derivative lawsuits, including putative stockholder complaints or stockholder class action complaints, as a result of our entry into the Amended Merger Agreement. Securities class action lawsuits and derivative lawsuits are often brought against public companies that have entered into merger agreements. The outcome of litigation is uncertain and we may not be successful in defending against future claims brought against us even if they are without merit. Regardless of the outcome, any such lawsuits or enforcement proceedings commenced against us in connection with the Merger could delay or prevent completion of the Merger, including through an injunction prohibiting completion, require significant time and resources, divert the attention of our management and employees from our day-to-day business, result in substantial costs and otherwise adversely affect our business, financial condition or results of operations. Adverse judgments or settlements could have a negative impact on our liquidity and financial condition.

Read in the 10-Q

Our executive officers and directors may have interests in the proposed Merger that are different from, or in addition to, those of our stockholders generally.

Read in the 10-Q

Our executive officers and directors may have interests in the proposed Merger that are different from the interests of our stockholders generally, including, among others, the acceleration of the vesting of equity awards, receipt by certain executive officers of severance payments and benefits upon a qualifying termination within a set time period following the Merger, and continued indemnification following the Merger. These interests, among others, may influence, or appear to influence, our executive officers and directors and cause them to view the Merger differently from how our stockholders generally may view it.

Read in the 10-Q

Even if the Merger is completed, our stockholders will remain subject to certain risks relating to the Merger.

Read in the 10-Q

If the Merger is consummated, each share of our common stock (other than certain excluded shares, including the shares held by rollover stockholders) held by our stockholders immediately prior to the Effective Time will be cancelled and automatically cease to exist and will be converted into the right to receive $25.00 per share in cash and any Additional Consideration, as applicable, without interest, subject to applicable withholding taxes. Risks to our stockholders include:

Read in the 10-Q

• The Per Share Consideration is fixed and will not be adjusted for changes in our business, assets, liabilities, prospects, outlook, financial condition or operating results or in the event of any change in the market price of, analyst estimates of, or projections relating to, our common stock;

Read in the 10-Q

• Other than the rollover stockholders, our current stockholders will not participate in any future growth of our business or benefit from any future increase in its value; and

Read in the 10-Q

• Receipt of the Merger Consideration under the Amended Merger Agreement is taxable to stockholders that are treated as U.S. holders for U.S. federal income tax purposes.

Read in the 10-Q

Item 6

2.1* Agreement and Plan of Merger, dated as of October 23, 2026, by and among Surgery Partners, Inc., Spyglass Topco, LLC, Spyglass Merger Subsidiary, Inc. and, solely for the limited purposes set forth therein, Bon Secours Mercy Health, Inc. (incorporated herein by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed October 26, 2026).

Read in the 10-Q

2.2 Amendment No. 1 to the Agreement and Plan of Merger, dated as of November 8, 2026, by and among the Company, Parent, Merger Subsidiary and Guarantor (incorporated herein by reference to Exhibit 2.2 to the Company’s Current Report on Form 8-K filed November 9, 2026).

Read in the 10-Q

10.1* Voting and Support Agreement, dated as of October 23, 2026, by and among Spyglass Topco, LLC, Surgery Partners, Inc. and the Reinvestment Stockholders party thereto (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed October 26, 2026).

Read in the 10-Q

10.2 Securities Purchase Agreement by and among IHC Health Services, Inc., Mountain View Hospital, LLC, SMBI Idaho, LLC, and Surgery Partners, Inc. dated September 14, 2026.

Read in the 10-Q

10.3 Securities Purchase Agreement by and among IHC Health Services, Inc., Idaho Falls Community Hospital, LLC, SMBI Idaho, LLC, and Surgery Partners, Inc. dated September 14, 2026.

Read in the 10-Q

101. INS Inline XBRL Taxonomy Extension Instance Document - the instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document.

Read in the 10-Q

104 The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, formatted in Inline XBRL (included in Exhibit 101).

Read in the 10-Q

* Certain schedules and exhibits have been omitted pursuant to Instruction 4 of Item 1.01 and in accordance with Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted exhibit or schedule to the SEC upon its request.

Read in the 10-Q

The 10-Q's risk factors against the 10-K

Item 1A of the 10-Q filed Nov 9, 2026 against Item 1A of the 10-K filed Mar 2, 2026. A 10-Q repeats only the risks that changed, so a 10-K paragraph that is missing from it is not counted as removed. Added is a paragraph with nothing like it in the 10-K, Reworded a sentence that is in both with several words changed, Quiet changes a sentence in both where one to four words changed and one is a hedge or a modal (cut words struck through, new words highlighted). Text on the page, not a score; each links to the filing at sec.gov.

What the 10-Q itself says about its risk factors:As of September 30, 2026, there have been no material changes with respect to the risk factors discussed in our 2025 Annual Report on Form 10-K, except as described below:

Read in the 10-Q
Added10-Q Nov 9, 2026 vs 10-K Mar 2, 2026
We may not complete the Merger within the anticipated timeframe, or at all, which could have a material adverse impact on our business, financial condition or results of operations, as well as negatively impact the per share price of our common stock.

Read it in the 10-Q at sec.gov

Added10-Q Nov 9, 2026 vs 10-K Mar 2, 2026
On October 23, 2026, we entered into the Original Merger Agreement which was further amended on November 8, 2026 by the Merger Agreement Amendment. For more information, see Note 11, Subsequent Events, in Item 1 of this report. The consummation of the Merger is subject to the satisfaction or waiver, to the extent permitted by law, of certain customary closing conditions, as set forth in the Amended Merger Agreement, including, but not limited to: (i) the adoption of the Amended Merger Agreement by the Company’s stockholders; (ii) the expiration or termination of any applicable waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended; and (iii) the absence of any law or order enjoining or otherwise prohibiting the Merger. In addition, the obligation of each party to consummate the Merger is conditioned upon the other party’s representations and warranties being true in all respects (subject to certain customary materiality exceptions) and the other party having performed in all material respects its covenants, obligations and conditions under the Amended Merger Agreement. The obligation of Parent and Merger Subsidiary to consummate the Merger is also subject to the absence of a Material Adverse Effect (as defined in the Amended Merger Agreement) on the Company that is continuing. A number of the conditions to completion of the Merger are not within our control, and, in addition, the Merger may fail to close for other reasons. We cannot provide any assurance that the Merger will be consummated on the terms specified in the Amended Merger Agreement, within the anticipated timeframe or at all.

Read it in the 10-Q at sec.gov

Added10-Q Nov 9, 2026 vs 10-K Mar 2, 2026
Failure to complete the Merger within the anticipated timeframe, or at all, could adversely affect our business and the market price of our common stock in a number of ways, including:

Read it in the 10-Q at sec.gov

Added10-Q Nov 9, 2026 vs 10-K Mar 2, 2026
• The price of our common stock may decline to the extent that current market price of our common stock reflects assumptions that the Merger will be completed and/or completed on a timely basis;

Read it in the 10-Q at sec.gov

Added10-Q Nov 9, 2026 vs 10-K Mar 2, 2026
• The failure to complete the Merger may result in negative publicity and negatively affect our relationship with our stockholders, employees or our other business relationships;

Read it in the 10-Q at sec.gov

Show the other 7
Added10-Q Nov 9, 2026 vs 10-K Mar 2, 2026
• If the Merger is not completed, the time and resources committed by our management team could have been devoted to pursuing other business opportunities and initiatives; and

Read it in the 10-Q at sec.gov

Added10-Q Nov 9, 2026 vs 10-K Mar 2, 2026
• Under specified circumstances, upon termination of the Amended Merger Agreement, we may be required to pay Parent a termination fee of approximately $149.1 million and reimburse Parent for certain reasonable and documented out-of-pocket expenses incurred in connection with the Merger, up to an aggregate cap of $8.25 million. These payments could have a material adverse impact on our business, financial condition, or results of operations.

Read it in the 10-Q at sec.gov

Added10-Q Nov 9, 2026 vs 10-K Mar 2, 2026
The announcement and pendency of the Merger could materially adversely affect our business, financial condition or results of operations, as well as negatively impact the share price of our common stock.

Read it in the 10-Q at sec.gov

Added10-Q Nov 9, 2026 vs 10-K Mar 2, 2026
The pending Merger, and the announcement thereof, as well as any delays in the expected timeframe, could cause disruption in and create uncertainties, which could have an adverse effect on our business, operating results, financial condition and trading price of our common stock, regardless of whether the Merger is completed, and could cause us not to realize some or all of the benefits that we expect to achieve if the Merger is successfully completed within its expected timeframe. These risks include, but are not limited to:

Read it in the 10-Q at sec.gov

Added10-Q Nov 9, 2026 vs 10-K Mar 2, 2026
• A substantial amount of our management’s and employees’ attention has been and will continue to be directed toward the consummation of the Merger and thus is being diverted from our day-to-day operations;

Read it in the 10-Q at sec.gov

Added10-Q Nov 9, 2026 vs 10-K Mar 2, 2026
• There may be potential adverse reactions or changes to business relationships with our customers, health system and joint venture partners, suppliers, vendors, employees and other business partners resulting from the announcement or completion of the Merger, including if existing or potential business partners or employees attempt to negotiate changes in existing business

Read it in the 10-Q at sec.gov

Added10-Q Nov 9, 2026 vs 10-K Mar 2, 2026
relationships, consider entering into business relationships with parties other than us, delay or defer decisions concerning their business with us, or terminate their existing business relationships with us while the Merger is pending; and

Read it in the 10-Q at sec.gov

The first 12 of 28 are shown (at most 12 of each type).

Phrases used for the first time

Two-word phrases in Risk Factors of the 10-K filed Mar 2, 2026 that are in none of the 1 earlier 10-Ks stored, back to Mar 7, 2025

healthcare laws ×2laws regulations ×2regulations policies ×2premium caps ×2healthcare industry ×2
Where each one is used
  • healthcare laws: •We cannot predict the effect that changes in healthcare laws, regulations, policies and government programs may have on our business, financial condition or results of operations.
  • laws regulations: •We cannot predict the effect that changes in healthcare laws, regulations, policies and government programs may have on our business, financial condition or results of operations.
  • regulations policies: •We cannot predict the effect that changes in healthcare laws, regulations, policies and government programs may have on our business, financial condition or results of operations.
  • premium caps: Over the past several years, various laws and regulations lengthened the enrollment period, expanded income eligibility, and reduced premium caps for subsidies for individuals purchasing Affordable Care Act coverage through state and federal marketplaces. However, several of these provisions – notably, those...
  • healthcare industry: Over the past several years, various laws and regulations lengthened the enrollment period, expanded income eligibility, and reduced premium caps for subsidies for individuals purchasing Affordable Care Act coverage through state and federal marketplaces. However, several of these provisions – notably, those...

The 10-K at sec.gov

Used at least twice, small words left out. Counted, not picked: a phrase can be new because the company renamed something.

What was taken out

3 paragraphs of last year's Risk Factors with nothing like them now. The longest are quoted.

Across all companies
The Affordable Care Act has changed and continues to change how health care services are covered, delivered and reimbursed through, among other things, expanded coverage of uninsured individuals, reduced growth in Medicare program spending and the establishment and expansion of programs tying reimbursement to quality and clinical integration. The Affordable Care Act also reforms certain aspects of health insurance, quality of care and fraud and abuse enforcement.
In the 10-K filed Mar 7, 2025
Our amended and restated certificate of incorporation (the "Certificate of Incorporation") provides that, subject to certain exceptions and to the fullest extent permitted by applicable law, the Court of Chancery of the State of Delaware (the "Court of Chancery") will be the sole and exclusive forum for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a
In the 10-K filed Mar 7, 2025
temporary personnel. We also depend on the available labor pool of semi-skilled and unskilled workers in each of the markets in which we operate.
In the 10-K filed Mar 7, 2025

Sources

Item 1A of each 10-K and 10-Q on EDGAR, quoted exactly. Each paragraph links to the filing at sec.gov.

Also

10-K change: what was reworded or cut, section by section.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/SGRY/export.csv") into a cell.

Next:10-K change
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.